[go: up one dir, main page]

AU4990599A - Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization - Google Patents

Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization

Info

Publication number
AU4990599A
AU4990599A AU49905/99A AU4990599A AU4990599A AU 4990599 A AU4990599 A AU 4990599A AU 49905/99 A AU49905/99 A AU 49905/99A AU 4990599 A AU4990599 A AU 4990599A AU 4990599 A AU4990599 A AU 4990599A
Authority
AU
Australia
Prior art keywords
upregulation
agents
nitric oxide
endothelial cell
type iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49905/99A
Inventor
James K. Liao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/115,387 external-priority patent/US6423751B1/en
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU4990599A publication Critical patent/AU4990599A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU49905/99A 1998-07-14 1999-07-14 Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization Abandoned AU4990599A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09115387 1998-07-14
US09/115,387 US6423751B1 (en) 1998-07-14 1998-07-14 Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US27322499A 1999-03-19 1999-03-19
US09273224 1999-03-19
PCT/US1999/015827 WO2000003746A2 (en) 1998-07-14 1999-07-14 Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization

Publications (1)

Publication Number Publication Date
AU4990599A true AU4990599A (en) 2000-02-07

Family

ID=26813141

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49905/99A Abandoned AU4990599A (en) 1998-07-14 1999-07-14 Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization

Country Status (2)

Country Link
AU (1) AU4990599A (en)
WO (1) WO2000003746A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239172B1 (en) 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US5968983A (en) 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
AU2002243883A1 (en) * 2001-02-07 2002-08-19 The Mclean Hospital Corporation Cholesterol-lowering agents as treatment for psychological and cognitive disorders
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
TWI241190B (en) 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
PE20020856A1 (en) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-TETRAHYDRONAFTIL ACILATED AMINES
PE20020870A1 (en) 2001-02-13 2002-11-18 Aventis Pharma Gmbh 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL ACILATED AMINES
EP1249244A1 (en) 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
AU2002349411A1 (en) * 2001-11-30 2003-06-17 Asahi Kasei Pharma Corporation Remedies for primary pulmonary hypertension
FR2833839A1 (en) * 2001-12-21 2003-06-27 Rytek Use of pulmonary epithelial cell myosin contraction inhibitors for the treatment or prevention of respiratory disorders such as asthma, allergies, and chronic obstructive lung diseases.
FR2833840B1 (en) * 2001-12-21 2010-06-18 Rytek METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY PATHOLOGIES
FR2837103B1 (en) * 2002-03-15 2004-07-09 Rytek COMPOSITIONS FOR THE TREATMENT OF DIGESTIVE FUNCTIONAL CONDITIONS
JP2005526772A (en) * 2002-03-15 2005-09-08 リテック Composition for treating digestive function pathology
FR2844201A1 (en) * 2002-09-06 2004-03-12 Rytek Use of compound that controls the opening of intestinal epithelium tight junctions for prevention and cure of hyperalgesic intestinal disorders
ES2573471T3 (en) 2002-05-09 2016-06-08 The Brigham And Women's Hospital, Inc. 1L1RL-1 as a marker of cardiovascular diseases
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7105513B2 (en) 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
CA2400254A1 (en) * 2002-09-19 2004-03-19 University Health Network Compositions and methods for treating heart disease
US7132536B2 (en) 2003-04-24 2006-11-07 Sanofi-Aventis Deutschland Gmbh Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
MXPA06005451A (en) 2003-11-17 2007-01-26 Biomarin Pharm Inc Treatment of phenylketonurias with bh4.
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US20080312189A1 (en) * 2004-03-05 2008-12-18 Eisai Co., Ltd. Cadasil Treatment with Cholinesterase Inhibitors
FR2879100B1 (en) 2004-12-09 2007-07-06 Lionel Bueno COMPOSITIONS FOR THE TREATMENT OF OCULAR SURFACE PATHOLOGIES AND RETINA
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
ATE551059T1 (en) 2005-10-26 2012-04-15 Asahi Kasei Pharma Corp FASUDIL IN COMBINATION WITH BOSENTAN FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
EP1905764A1 (en) 2006-09-30 2008-04-02 Sanofi-Aventis Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals
EP1923062A1 (en) 2006-11-16 2008-05-21 sanofi-aventis Imidazo[2,1-b]thiazoles and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
JP2011519973A (en) * 2008-05-12 2011-07-14 アムネスティックス・インコーポレーテッド Information about compound-related applications to improve learning and memory
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN113993523A (en) 2019-04-17 2022-01-28 指南针探路者有限公司 Treatment of depression and other various disorders with siloxibin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583287D1 (en) * 1984-12-27 1991-07-25 Asahi Chemical Ind SUBSTITUTED ISOCHINOLINSULFONYL COMPOUNDS.
JPS6287581A (en) * 1985-10-11 1987-04-22 Hokuriku Seiyaku Co Ltd Naphthalenesulfonamide derivative
JP2528451B2 (en) * 1986-07-09 1996-08-28 北陸製薬株式会社 Naphthalene sulfonamide derivative
WO1991006293A2 (en) * 1989-11-01 1991-05-16 University Of Vermont And State Agricultural College Composition containing 2,3-butanedione monoxime and method for reversibly arresting muscle activity
JPH0725786A (en) * 1990-05-16 1995-01-27 Univ Rockefeller Medical treatment of amyloidosis accompanying alzheimer desease
JP2893029B2 (en) * 1992-08-10 1999-05-17 旭化成工業株式会社 Cardioprotectant
US5519035A (en) * 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
WO1995014465A2 (en) * 1993-11-22 1995-06-01 The Johns Hopkins University Methods for amelioration of immunodeficiency virus induced neurodegeneration by covering nitric oxide or superoxide concentration
US5830910A (en) * 1995-10-23 1998-11-03 University Of Kentucky Research Foundation Cytochalasins useful in providing protection against nerve cell injury associated with neurodegenerative disorders
US5856360A (en) * 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
AU5977598A (en) * 1997-02-07 1998-08-26 Synapse Pharmaceutical International, Inc. Pharmaceutical composition for treatment of synaptic dysfunction comprising an oxime
WO1999000117A2 (en) * 1997-06-27 1999-01-07 Ontogeny, Inc. Neuroprotective methods and reagents
US6180597B1 (en) * 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors

Also Published As

Publication number Publication date
WO2000003746A3 (en) 2000-04-20
WO2000003746A2 (en) 2000-01-27

Similar Documents

Publication Publication Date Title
AU4990599A (en) Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
AU2002211378A1 (en) High performance lithium or lithium ion cell
AU2001253077A1 (en) Electrochemical cell and assembly for same
AU2002246664A1 (en) Lipid-based nitric oxide donors
AU1313800A (en) Planar fuel cell
NO20006044D0 (en) Nitric oxide synthase inhibitors
DE69929756D1 (en) fuel cell stack
ZA98179B (en) Nitric oxide synthase inhibitors.
GB2372627B (en) Fuel cell and fuel cell stack
AU2001292539A1 (en) Fuel cell assembly and method for making the same
AU2001245749A1 (en) Fuel cell stack assembly
AU2001271241A1 (en) Uninterruptible power supplies employing fuel cells
WO2000077652A3 (en) Sequence partitioning in cell structures
AU2001290238A1 (en) Electrode for lithium secondary cell and lithium secondary cell
AU2002359270A1 (en) Improved solid oxide fuel cells and interconnectors
AU5901601A (en) Fuel cell and power chip technology
MXPA01009977A (en) Non-aqueous electrolyte cell and solid electrolyte cell.
AU2002212716A1 (en) Nonaqueous lithium secondary cell
EP1450429A4 (en) Fuel cell stack
AU2001276298A1 (en) High temperature fuel cell
AU4040499A (en) Electrochemical cell
AU2001227085A1 (en) Electrode for lithium cell and lithium secondary cell
AU2003224637A1 (en) High performance fuel cells
AU4685799A (en) Telomerase inhibitors
AUPP297298A0 (en) Charge storage devices

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase